茲 提 述 瑋 俊 生 物 科 技 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 四 月 十 四 日 及 二 零 二 五 年 五 月 十 五 日 的 公 告，內 容 有 關 建 議 根 據 特 別 授 權 發 行 新 可 換 股 債 券 的 關 連交易，及日期為二零二五年五月十四日、二零二五年六月十日、二零二五年六 月 二 十 五 日、二 零 二 五 年 七 月 十 五 日、二 零 二 五 年 七 月 三 十 一 日 及 二 零 二 五 年 八 月 十 五 日 的 公 告，內 容 有 關 延 遲 寄 發 通 函（「該等公告」）。除 另 有 所 指 外，本 公 告所用詞彙與該等公告所界定者具有相同涵義。 第二份補充協議 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。 瑋俊生物科技有限公司 Wai Chun Bio-Technology Limited （於開曼群島註冊成立之有限公 ...

Group 1: Financial Performance - Fuyao Glass reported a net profit of 4.805 billion yuan for the first half of the year, representing a year-on-year increase of 37.33% [13] - The company plans to distribute a cash dividend of 9 yuan per 10 shares (including tax) [13] - Xiaomi Group achieved total revenue of 116 billion yuan in the second quarter, marking a year-on-year growth of 30.5% [13] Group 2: Market Trends and Policies - The Ministry of Finance reported that from January to July, the securities transaction stamp duty reached 93.6 billion yuan, a year-on-year increase of 62.5% [10] - The People's Bank of China announced an additional 100 billion yuan in re-lending to support small and micro enterprises in disaster-affected areas [10] - The Shanghai Municipal Economic and Information Commission released a plan to accelerate the integration of AI and manufacturing [11] Group 3: Corporate Developments - Dongjie Intelligent announced a planned change in control, leading to a suspension of its stock and convertible bonds [14] - Pengding Holdings plans to invest 8 billion yuan in the Huai'an Industrial Park to expand production capacity for AI applications [15] - Tesla launched a new Model Y L vehicle in China, with a starting price of 339,000 yuan [15]

Group 1 - The core point of the article is that Chen Guanyu, a shareholder of Weijun Biotechnology (00660.HK), increased his stake in the company by purchasing 660,000 shares at an average price of HKD 0.232 per share, totaling approximately HKD 153,100 [1]. - Following this transaction, Chen Guanyu's total shareholding increased to 14,787,040 shares, raising his ownership percentage from 7.92% to 8.29% [1][3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 瑋俊生物科技有限公司 Wai Chun Bio-Technology Limited （於開曼群島註冊成立之有限公司） （股份代號：660） 延遲寄發通函 茲 提 述 瑋 俊 生 物 科 技 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 四 月 十 四 日、二 零 二五年五月十四日、二零二五年六月十日、二零二五年六月二十五日、二零二五 年 七 月 十 五 日 及 二 零 二 五 年 七 月 三 十 一 日 的 公 告，內 容 有 關 擬 議 根 據 特 別 授 權 發 行 新 可 換 股 債 券 的 關 連 交 易 以 及 延 遲 寄 發 通 函（「該等公告」）。除 另 有 所 指 外， 本公告所用詞彙與該等公告所界定者具有相同涵義。 誠 如 該 公 告 所 披 露，當 中 載 有（其 中 包 括）(i)認 購 事 項 以 及 擬 據 此 進 行 的 交 易（包 括 授 出 新 可 換 股 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑋俊生物科技有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00660 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 400,000,000 | HKD | | 0.25 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 400,000,000 | HKD | | 0.25 | HKD | | 100,000,000 | | 2. 股份分 ...

茲 提 述 瑋 俊 生 物 科 技 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 四 月 十 四 日、二 零 二 五 年 五 月 十 四 日、二 零 二 五 年 六 月 十 日、二 零 二 五 年 六 月 二 十 五 日 及 二 零 二 五 年 七 月 十 五 日 的 公 告，內 容 有 關 擬 議 根 據 特 別 授 權 發 行 新 可 換 股 債 券 的 關 連 交 易 以 及 延 遲 寄 發 通 函（「該等公告」）。除 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 等 公 告所界定者具有相同涵義。 誠 如 該 公 告 所 披 露，當 中 載 有（其 中 包 括）(i)認 購 事 項 以 及 擬 據 此 進 行 的 交 易（包 括 授 出 新 可 換 股 債 券 特 別 授 權）的 進 一 步 資 料；(ii)獨立董事委員會就認購協議向 獨立股東提供的推薦建議；(iii)獨立財務顧問函件；(iv)新可換股債券的詳情，連 同(v)股 東 特 別 大 會 通 告 的 通 函（「通 函」）預 計 將 於 二 零 二 五 年 七 月 三 十 一 日（星 期 四）或 之 前 寄 發 予 股 ...

Core Viewpoint - Fuyao is expected to achieve significant revenue growth and improved profitability in 2Q25, driven by various factors including better scale effects, reduced OEM rebate pressure, and cost savings from raw material and shipping cost deflation [1][2][3]. Revenue Growth - 2Q25 revenue is projected to grow by 13-14% YoY, reaching RMB10.7-10.8 billion, with domestic automotive glass revenue expected to rise over 15% YoY [2][3]. - Overseas auto glass sales are anticipated to see double-digit YoY growth, supported by increased production capacity at the US second-phase plant and steady export demand to Europe [2][3]. Profitability and Margins - Gross margin for 2Q25 is expected to expand by over 1 percentage point from 35.4% in 1Q25, aided by improved operational efficiencies and cost savings [1][2]. - The company is projected to achieve net income of RMB2.5-2.6 billion in 2Q25, marking another quarterly high, with FX gains estimated at over RMB300 million due to the Euro's appreciation against the RMB [1][3]. Overseas Operations - US manufacturing profitability is expected to improve, with the first-phase plant's capacity utilization and operational efficiency enhancing overall profitability [3]. - The second-phase plant is on track to narrow its losses compared to 2H24, with full-year operating margin expected to exceed the original target of 13% [3]. Strategic Positioning - Fuyao is leading among Chinese auto parts suppliers in expanding its global footprint, particularly in the US market, by leveraging local capacity and export supply [4]. - The company's flexible capacity allocation strategy amid tariff uncertainties enhances its operational resilience and risk resistance in a challenging geopolitical environment [4]. Valuation and Market Position - Fuyao's H-shares are currently trading at 16x 2025 P/E, which is considered undemanding, especially compared to peers like Nexteer and Minth [5]. - The anticipated solid operating performance in 2Q25 is expected to act as a catalyst for reversing the company's lagging stock price performance year-to-date [5].

董事会已审视及探求不同途径清偿股东贷款及其他贷款(连同应计利息)，并认为发行新可换股债券是降 低集团每年产生的利息开支金额、提升集团的财务状况及削减集团的资本负债比率的最有效及合适的方 法，原因在于新可换股债券每年2%的较低利率，将可尽量减轻集团的短期财政负担因三年总共能节省 利息约191.25万港元;集团的净流动负债也将改善，因认购事项生效后股东贷款及其他贷款(连同应计利 息)将从流动负债重新分类为非流动负债;公司赎回新可转换债券的财务压力减少因为新可转换债券到期 时赎回折扣为2%;股东贷款及其他贷款的本金额(连同应计利息)将于新可换股债券换股权获悉数行使后 全数清偿，毋须公司任何现金流出;及发行新可换股债券将不会对公司股权造成即时摊薄影响。 新可换股债券附带换股权，可按新可换股债券换股价每股新可换股债券换股股份0.07港元(可予调整)转 换为约2.14亿股新可换股债券换股股份。现有债券持有人一根据认购协议应付的认购款项将透过抵销公 司应付予现有债券持有人一及╱或其联系人的股东贷款及其他贷款(预期于完成日期将为1500万港元)项 下的未偿还本金额及应计利息而偿付。 玮俊生物科技(00660)公布，于2025 ...

Financial Performance - The company reported revenue of approximately HKD 161,056,000 for the six months ended December 31, 2024, a decrease of 15.4% compared to HKD 190,330,000 for the same period in 2023[8]. - Gross profit for the same period was approximately HKD 21,130,000, with a gross margin of 13.1%, compared to a gross profit of HKD 16,795,000 and a margin of 8.8% in the previous year, reflecting an increase of HKD 4,335,000 and 4.3% respectively[8]. - The company recorded a loss attributable to owners of approximately HKD 13,661,000, compared to a loss of HKD 6,734,000 in the same period last year, mainly due to impairment losses on receivables and increased depreciation and finance costs[9]. - The company incurred a loss before tax of HKD 11,202,000, compared to a loss of HKD 2,845,000 in the prior year, indicating a significant increase in losses[37]. - The net loss for the period was HKD 13,054,000, compared to a net loss of HKD 4,030,000 in the same period last year, reflecting a worsening financial performance[37]. - Basic and diluted loss per share was HKD 7.97, compared to HKD 3.93 in the previous year, indicating a higher loss per share[37]. - The company reported a net other comprehensive loss of HKD 510,000 for the period, compared to a gain of HKD 5,530,000 in the previous year[39]. - The company reported a loss attributable to shareholders of approximately HKD 13,661,000 for the six months ended December 31, 2024, compared to a loss of HKD 6,734,000 for the same period in 2023[67]. Expenses and Costs - Administrative expenses increased by 28.8% to approximately HKD 12,126,000, primarily due to increased depreciation of property, plant, and equipment in China[8]. - The company incurred a depreciation expense for property, plant, and equipment of HKD 6,585,000 for the six months ended December 31, 2024, compared to HKD 3,691,000 in the previous year[65]. - Employee costs, including director remuneration, amounted to approximately HKD 4,189,000 for the six months ending December 31, 2024, compared to HKD 3,591,000 for the same period in 2023[28]. - Interest expenses paid to the ultimate holding company amounted to HKD 139,000 for the six months ended December 31, 2024, compared to HKD 78,000 in the same period of 2023, reflecting an increase of 78.2%[75]. - The total salary for key management members increased to HKD 618,000 in the six months ended December 31, 2024, up from HKD 262,000 in the same period of 2023, representing a growth of 135.5%[77]. Debt and Liabilities - Total debt as of December 31, 2024, was approximately HKD 146,879,000, up from HKD 135,902,000 as of June 30, 2024[10]. - The net debt to total assets ratio was approximately 80.5% as of December 31, 2024, compared to 63.8% as of June 30, 2024[10]. - The company incurred a loss of HKD 13,661,000 during the reporting period, contributing to a total equity deficit of HKD (93,174,000) as of December 31, 2024[45]. - The company’s total liabilities exceeded total assets, resulting in a net asset deficiency of HKD (57,072,000) as of December 31, 2024[40]. Assets - As of December 31, 2024, non-current assets totaled HKD 87,468,000, down from HKD 95,100,000 as of June 30, 2024, representing a decrease of approximately 8.5%[40]. - Current assets decreased to HKD 92,870,000 from HKD 114,398,000, reflecting a decline of about 18.8%[40]. - The company’s trade receivables as of December 31, 2024, amounted to HKD 25,064,000, a decrease from HKD 34,945,000 as of June 30, 2024[69]. - The provision for impairment of trade receivables was HKD 1,953,000 as of December 31, 2024, compared to HKD 5,785,000 as of June 30, 2024[69]. - Cash and cash equivalents at the end of the period were HKD 1,784,000, down from HKD 2,161,000 at the beginning of the period[47]. Corporate Governance - The company is currently seeking suitable candidates to fill vacancies in the audit committee to comply with listing rules, following the resignation of a director[36]. - The audit committee is composed of two independent non-executive directors, which is below the required minimum of three members as per listing rules[36]. - The company has adopted corporate governance principles as per the listing rules, although it has not separated the roles of Chairman and CEO, which is a deviation from the guidelines[32]. - The company has adopted the Standard Code for Directors' Securities Transactions as per the Listing Rules Appendix C3, and all directors confirmed compliance during the six months ending December 31, 2024[31]. Strategic Plans and Market Position - The company aims to continue strategic acquisitions to capture new opportunities in the Chinese market and strengthen its revenue and profit base[13]. - The company is actively seeking growth projects for acquisition or investment and is in discussions with various parties regarding such opportunities[13]. - The board believes that the company will have sufficient cash resources to meet its operational funding and other financing needs for the next twelve months[53]. - The company is in discussions with potential investors to raise sufficient funds through financing arrangements[55]. Shareholder Information - The major shareholder, Mr. Lin Qingqu, holds 268,072,400 shares, representing approximately 156.33% of the issued shares[22]. - Onward Global Investments holds 12,863,500 shares, representing approximately 7.50% of the issued shares[22]. - Fair Concourse Limited holds 14,127,040 shares, representing approximately 8.24% of the issued shares[23]. - The company has not declared any interim dividends for the six months ended December 31, 2024[66]. Compliance and Reporting - The company has adopted all new and revised Hong Kong Financial Reporting Standards effective from July 1, 2023, with no significant impact on its financial performance or position expected[56]. - The company has no significant investments or capital asset plans as of December 31, 2024, apart from necessary capital expenditures for operations[17]. - There were no purchases, sales, or redemptions of any listed securities by the company or any of its subsidiaries during the six months ending December 31, 2024[30].

Financial Performance - For the six months ended December 31, 2024, the company reported revenue of HKD 161,056,000, a decrease of 15.4% compared to HKD 190,330,000 for the same period in 2023[2]. - The gross profit for the same period was HKD 21,130,000, representing a gross margin of 13.1%, compared to HKD 16,795,000 in 2023[2]. - The company incurred a loss before tax of HKD 11,202,000, compared to a loss of HKD 2,845,000 in the previous year, indicating a significant increase in losses[3]. - The net loss for the period was HKD 13,054,000, compared to HKD 4,030,000 in 2023, reflecting a year-over-year increase of 224.5%[3]. - Basic and diluted loss per share was HKD 7.97, compared to HKD 3.93 for the same period last year[3]. - The company reported a total comprehensive loss of HKD 13,564,000 for the period, compared to a comprehensive income of HKD 1,500,000 in the previous year[5]. - The group reported a loss attributable to the owners of the company of approximately HKD 13,661,000 for the six months ending December 31, 2024, compared to a loss of HKD 4,030,000 for the same period in 2023[12][22]. - The loss attributable to the company's owners increased to approximately HKD 13,661,000 for the six months ending December 31, 2024, compared to approximately HKD 6,734,000 for the six months ended December 31, 2023[39]. Assets and Liabilities - Non-current assets decreased to HKD 87,468,000 from HKD 95,100,000 as of June 30, 2024[7]. - Current assets also declined to HKD 92,870,000 from HKD 114,398,000, indicating a reduction in liquidity[7]. - Total liabilities amounted to HKD 237,410,000, down from HKD 253,847,000, showing a decrease in overall debt[8]. - The company's equity attributable to owners was a loss of HKD 93,174,000, compared to a loss of HKD 79,253,000 as of June 30, 2024[8]. - The net current liabilities of the group as of December 31, 2024, were approximately HKD 144,540,000, indicating significant uncertainty regarding the group's ability to continue as a going concern[12]. - Total debt as of December 31, 2024, was approximately HKD 146,879,000, up from approximately HKD 135,902,000 as of June 30, 2024[40]. - The net debt to total assets ratio increased to approximately 80.5% as of December 31, 2024, compared to approximately 63.8% as of June 30, 2024[40]. Revenue Sources - For the six months ending December 31, 2024, the revenue from the manufacturing and sales of modified starch and other biochemical products was approximately HKD 161,056,000, a decrease of 15.4% compared to HKD 190,330,000 for the same period in 2023[17][18]. - The group’s segment profit from modified starch and other biochemical products was HKD 4,522,000 for the six months ending December 31, 2024, down from HKD 7,959,000 for the same period in 2023[22]. - Segment profit from the manufacturing and sales of modified starch and biochemical products was approximately HKD 4,522,000 for the review period, down from approximately HKD 7,959,000 for the six months ended December 31, 2023[42]. Strategic Plans - The group plans to pursue strategic acquisitions to gain new opportunities in the Chinese market and strengthen its revenue and profit base[14]. - The group is actively seeking projects with growth potential for acquisition or investment and is in discussions with various parties regarding such opportunities[14]. - The company is actively seeking acquisition opportunities to gain new market opportunities in China and strengthen its revenue and profit base[42]. - The company is implementing measures to improve its financial situation, including discussions with potential investors to raise sufficient funds[42]. Expenses and Financial Management - Administrative expenses increased by 28.8% from approximately HKD 9,412,000 for the six months ended December 31, 2023, to approximately HKD 12,126,000 for the six months ending December 31, 2024[39]. - Sales expenses decreased by 27.7% from approximately HKD 6,938,000 for the six months ended December 31, 2023, to approximately HKD 5,432,000 for the six months ending December 31, 2024[39]. - The income tax expense for the six months ending December 31, 2024, was HKD 1,852,000, compared to HKD 1,185,000 for the same period in 2023[23]. Shareholder Information - The company did not recommend any interim dividend for the six months ended December 31, 2024, consistent with the previous period[27]. - The board has decided not to recommend an interim dividend for the six months ended December 31, 2024[44]. - The interim financial results for the six months ending December 31, 2024, will be published and sent to shareholders shortly[52]. Compliance and Governance - The audit committee currently consists of only two independent non-executive directors, which does not meet the minimum requirement of three members as per listing rules[51]. - The company is actively seeking suitable candidates to fill the vacancies in the audit committee to comply with listing rules by May 14, 2025[51]. Securities and Financing - The company has secured loans of approximately HKD 4,438,000 and has access to additional financing of approximately HKD 65,562,000 from its ultimate holding company to support its operations[12][16]. - The company has agreed to amend the terms of existing convertible bonds, including but not limited to the conversion price and maturity date[35]. - The company has not recognized any deferred tax liabilities due to the absence of taxable profits in Hong Kong for the periods under review[24]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ended December 31, 2024[45].